While the precise mechanisms underlying FCGBP expression in CRC development remain unclear, it is plausible to hypothesize that dysregulation of FCGBP may contribute to compromised mucosal immune defense, subsequently participating in intestinal inflammation. Here, FCGBP is linked to colorectal carcinoma.